Menu Search
Equities

Kalbe Farma Tbk PT

LCLA:STU

Kalbe Farma Tbk PT

Actions
  • Price (EUR)0.0785
  • Today's Change-0.002 / -1.88%
  • Shares traded0.00
  • 1 Year change-4.85%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in IDRIncome statement in IDRView more

Year on year Kalbe Farma Tbk PT had net income fall -18.20% from 3.38tn to 2.77tn despite a 5.24% increase in revenues from 28.93tn to 30.45tn. An increase in the cost of goods sold as a percentage of sales from 60.19% to 62.40% was a component in the falling net income despite rising revenues.
Gross margin37.46%
Net profit margin9.65%
Operating margin12.27%
Return on assets11.09%
Return on equity14.37%
Return on investment14.03%
More ▼

Cash flow in IDRView more

In 2023, cash reserves at Kalbe Farma Tbk PT fell by 717.35bn. However, the company earned 2.91tn from its operations for a Cash Flow Margin of 9.55%. In addition the company used 1.14tn on investing activities and also paid 2.44tn in financing cash flows.
Cash flow per share83.80
Price/Cash flow per share18.68
Book value per share480.69
Tangible book value per share432.65
More ▼

Balance sheet in IDRView more

Kalbe Farma Tbk PT uses little debt in its capital structure as supported by a debt to capital ratio of 3.02%.
Current ratio4.15
Quick ratio2.56
Total debt/total equity0.0335
Total debt/total capital0.0302
More ▼

Growth rates in IDR

SmartText is unavailable
Div yield(5 year avg)1.88%
Div growth rate (5 year)3.58%
Payout ratio (TTM)46.55%
EPS growth(5 years)2.67
EPS (TTM) vs
TTM 1 year ago		4.86
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.